SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group shares are experiencing significant volatility following reports that Meta plans to commercialize its excess AI compute capacity, which investors fear could increase market competition and pressure neocloud profit margins. Despite the selling pressure, the community is heavily divided, with many long-term holders dismissing the news as market manipulation and an overblown 'ghost story,' arguing that existing multi-year capacity contracts and structurally tight AI demand remain fundamentally intact.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing significant selling pressure and negative sentiment, driven largely by reports that hyperscalers like Meta are exploring the commercialization of their own excess AI compute capacity. Shareholders are actively debating the company's long-term viability, expressing mounting frustration over persistent price declines and concerns regarding management's capital allocation and lack of major deal announcements.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently surging as investors bet on potential upcoming catalysts, including global expansion efforts and positive clinical trial momentum involving the company's immunotherapy platform. The community is actively discussing a possible short squeeze, fueled by heavy options activity and high short interest, while celebrating recent media exposure highlighting the potential of NK cell therapies.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors weigh significant collaborative momentum, including a new integration with Lockheed Martin and ongoing demand for its ISR and counter-UAS platforms, against persistent retail concerns regarding share dilution and insider selling. Community discourse is highly polarized, with intense debates focusing on whether the company's expanding backlog and high-profile defense partnerships justify current valuations or if aggressive short interest and structural headwinds will continue to pressure the price.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility driven by broader semiconductor sector rotation and investor concerns regarding AI oversupply, particularly following reports of competitors seeking to monetize excess compute capacity. While many investors are panicking over the sharp correction, others view the pullback as a necessary consolidation and a prime accumulation opportunity, citing Micron's robust long-term contracts and fundamental positioning in the high-demand memory market.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by recent FDA approvals for its diagnostic platforms and ongoing strategic partnerships with pharmaceutical leaders. The community is heavily focused on the company's high short interest and its potential as a long-term play in AI-integrated healthcare, with traders closely monitoring upcoming events and technical breakouts for momentum signals.

Anthropic

Anthropic is currently trending as investors focus on its momentum toward a potential IPO and its competitive positioning against other industry leaders in the AI sector. Community discussions are heavily centered on its recent regulatory interactions, major infrastructure partnerships, and the startup's rapid revenue growth, which have intensified debates over its long-term valuation and future market impact.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors digest its inclusion in the Dow Jones Industrial Average while weighing the impact of intensifying AI talent competition, where key researchers have departed for rival firms. Community discussion remains focused on these structural shifts, along with the broader debate surrounding the sustainability of heavy AI infrastructure spending and how hyperscalers will effectively monetize their recent capital outlays.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant downward pressure following reports that Meta plans to build a cloud infrastructure business to monetize its own excess AI compute capacity, sparking investor concerns over potential long-term competition and supply-side saturation. While the community remains divided, bulls are highlighting CoreWeave's locked-in, long-term contracts and institutional backing as evidence that the company remains resilient against this headline-driven volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently the center of intense debate as traders weigh the potential market impacts of the EU's MiCA deadline against ongoing volatility in crypto and broader tech sector rotations. While some community members point to the stock's role as critical infrastructure for institutional stablecoin projects as a long-term catalyst, others remain sharply focused on short-term technical resistance and persistent downward price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Key PointsThe chief medical officer of Monte Rosa Therapeutics reported selling 41,845 shares directly for a transaction value of approximately $882,000, based on a weighted average price of around $21.08 per share over June 23-24, 2026...

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-monte-rosa-therapeutics-inc-stock...

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 15,837,633 shares...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating an...

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 22.2%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling...

Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $103,398.05 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were sold at an average...

Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The shares were sold...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat...

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$24.02
Prev Close	$24.20
Open	$23.85
Dividend Yield	0.00%
50-Day Moving Average	$19.26
Beta	1.48
Avg. Volume	1.61M
PE Ratio	-14.76

52-Week High	$25.77
52-Week Low	$4.12
Market Capitalization	$2.04B
EPS (Annual)	-$0.465
Price to Book	3.88
Revenue Per Employee	$824,480.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLUEMonte Rosa Therapeutics Inc

Latest GLUE News